首页> 美国卫生研究院文献>Advances in Virology >HIV Drug Resistance-Associated Mutations in Antiretroviral Naïve HIV-1-Infected Latin American Children
【2h】

HIV Drug Resistance-Associated Mutations in Antiretroviral Naïve HIV-1-Infected Latin American Children

机译:抗逆转录病毒幼稚HIV-1感染的拉丁美洲儿童中与艾滋病毒抗药性相关的突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Our goal was to describe the presence of HIV drug resistance among HIV-1-infected, antiretroviral (ARV) naïve children and adolescents in Latin America and to examine resistance in these children in relation to drug exposure in the mother. Genotyping was performed on plasma samples obtained at baseline from HIV-1-infected participants in a prospective cohort study in Brazil, Argentina, and Mexico (NISDI Pediatric Study). Of 713 HIV-infected children enrolled, 69 were ARV naïve and eligible for the analysis. At enrollment, mean age was 7.3 years; 81.2% were infected with HIV perinatally. Drug resistance mutations (DRMs) were detected in 6 (8.7%; 95% confidence interval 3.1–18.2%) ARV-naïve subjects; none of the mothers of these 6 received ARVs during their pregnancies and none of the children received ARV prophylaxis. Reverse transcriptase mutations K70R and K70E were detected in 3 and 2 subjects, respectively; protease mutation I50 V was detected in 1 subject. Three of the 6 children with DRMs initiated ARV therapy during followup, with a good response in 2. The overall rate of primary drug resistance in this pediatric HIV-infected population was low, and no subjects had more than 1 DRM. Mutations associated with resistance to nucleoside reverse transcriptase inhibitors were the most prevalent.
机译:我们的目标是描述拉丁美洲的HIV-1感染的抗逆转录病毒(ARV)初生儿童和青少年中是否存在HIV耐药性,并研究这些儿童与母亲的药物暴露相关的耐药性。在巴西,阿根廷和墨西哥的一项前瞻性队列研究(NISDI儿科研究)中,对基线时从HIV-1感染者的血浆样本中进行了基因分型。在招募的713名受HIV感染的儿童中,有69名初次接受ARV并符合分析条件。入学时,平均年龄为7.3岁;围产期艾滋病毒感染率为81.2%。在6名(8.7%; 95%置信区间3.1–18.2%)无ARV的受试者中检测到耐药性突变(DRM);这六个母亲中,没有一个在怀孕期间接受过抗逆转录病毒治疗,也没有一个孩子进行过抗逆转录病毒预防。在3名和2名受试者中分别检测到逆转录酶突变K70R和K70E;在1名受试者中检测到蛋白酶突变I50V。 6例DRM患儿中有3例在随访期间开始抗逆转录病毒疗法,在2例中反应良好。该患儿HIV感染人群的原发耐药率总体较低,且受试者的DRM均不超过1例。与对核苷逆转录酶抑制剂的抗性相关的突变最为普遍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号